Mizuho lowered the firm’s price target on Biogen to $335 from $340 and keeps a Buy rating on the shares. The analyst updated biotech models post the Q2 earnings reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Biotech Duo Sage (NASDAQ:SAGE) and BioGen (NASDAQ:BIIB) Jump on Pricing Data
- Biotech Alert: Searches spiking for these stocks today
- Denali Therapeutics price target lowered to $31 from $37 at Wedbush
- Biogen price target lowered to $340 from $3500 at Truist
- Needham cuts Sage Therapeutics to Hold on reduced zuranalone opportunity